Financial Data and Key Metrics Changes - In Q4 2018, total revenue was $4 million, a 41% increase from $2.8 million in Q4 2017. For the full year 2018, total revenue reached $12 million, up 26% from $9.5 million in 2017 [15] - Product revenue in Q4 2018 was $3.8 million, a 50% increase from $2.6 million in Q4 2017. For 2018, product revenue was $11.5 million, a 31% increase from $8.8 million in 2017 [15] - Operating expenses for 2018 were $23.7 million, a decrease of $3 million compared to 2017, reflecting successful cost-saving initiatives [15] Business Line Data and Key Metrics Changes - The Saphyr system has shown strong revenue growth, particularly in Q4 2018, driven by its acceptance in target markets for genomic structural variation detection [7][10] - The Saphyr system is now capable of processing 42 whole human genomes per week, with a simplified workflow costing less than $500 per sample in consumables [8] Market Data and Key Metrics Changes - The company expanded its sales teams in China, the U.S., and Western Europe to support global growth, indicating a strong focus on international markets [13] - There was a 70% increase in human-centered publications utilizing Bionano technology in 2018, highlighting growing awareness and acceptance of the technology [10] Company Strategy and Development Direction - The company aims to continue expanding its market presence through investigator-led studies that document Saphyr's performance in digital cytogenetics [20] - Ongoing improvements to the Saphyr workflow are expected to expand its applications and enhance its market penetration [20] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about future growth, citing a long track record of revenue growth and the expectation of continued performance in similar ranges [25][33] - The company is focused on executing its global sales strategy and enhancing the Saphyr system's capabilities to drive adoption in clinical settings [20][36] Other Important Information - As of December 31, 2018, the company's cash balance was $16.5 million, bolstered by $41.5 million in financing commitments [16] - The company has entered into agreements for debt and equity financing, which are expected to generate approximately $11.5 million in proceeds [18] Q&A Session Summary Question: How many Saphyr units were sold in the quarter? - The company is not providing specific unit sales figures at this time but noted growth across both consumables and instruments [22][24] Question: What is the expected revenue growth for 2019? - The company refrained from providing specific guidance but indicated confidence in continuing growth trends similar to those seen in 2018 [25][33] Question: What caused the decline in gross margins in Q4? - Management noted fluctuations in gross margins but emphasized year-over-year growth in gross margin percentage and absolute dollars [26][27] Question: Why were SG&A expenses higher in Q4? - The increase is attributed to additional expenses related to being a public company, with expectations for moderate growth in operating expenses moving forward [28][29] Question: What are the drivers of adoption for the Saphyr system? - The company highlighted product enhancements and documented proof of performance from ongoing studies as key drivers for adoption [35][37]

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38613 Bionano Genomics, Inc. (Exact name of Registrant as specified in its Charter) Delaware 26-1756290 (State or other jurisdiction ...